These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33006784)

  • 1. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
    Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
    Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
    Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
    Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
    Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
    Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
    Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
    Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    Lafferty L; Treloar C; Guthrie J; Chambers GM; Butler T
    J Viral Hepat; 2017 Feb; 24(2):111-116. PubMed ID: 27778436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
    Rance J; Lafferty L; Treloar C;
    Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
    Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
    Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contextualising the social capital of Australian Aboriginal and non-Aboriginal men in prison.
    Lafferty L; Treloar C; Chambers GM; Butler T; Guthrie J
    Soc Sci Med; 2016 Oct; 167():29-36. PubMed ID: 27597539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons.
    Sheehan Y; Cochrane A; Treloar C; Grebely J; Tedla N; Lloyd AR; Lafferty L
    Int J Drug Policy; 2024 Aug; 130():104516. PubMed ID: 38996643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
    Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
    Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd).
    Sheehan Y; Lafferty L; Tedla N; Byrne M; Dawson O; Stewart S; Leber B; Habraken N; Lloyd AR
    Int J Drug Policy; 2024 Jul; 129():104461. PubMed ID: 38971019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
    J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the 'Surveillance and Treatment of Prisoners with Hepatitis C' project (SToP-C).
    Rance J; Lafferty L; Treloar C;
    Addiction; 2021 Oct; 116(10):2761-2769. PubMed ID: 33751739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.